Navicixizumab - Oncologie, Inc. - Moffitt Cancer Centre2 Jun 2020 23:40
This could be exciting. Join the dots.
Oncologie, Inc - Collaborating with Moffitt Cancer Centre to develop cancer treatments. Navicixizumab licensed to Oncologie, Inc.
Moffitt Cancer Centre collaborating with Memgen.
Navicixizumab (OMP-305B83) is an anti-DLL4/VEGF bispecific antibody designed to inhibit both Delta-like ligand 4 (“DLL4”) in the Notch cancer stem cell pathway as well as vascular endothelial growth factor (“VEGF”) and thereby induce potent anti-tumor responses while mitigating certain angiogenic-related toxicities.
Memgen
Memgen is developing new therapies to harness the power of the immune system to potentially cure cancer and to protect people from COVID-19 and other diseases.
The Company's lead cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen expects to begin clinical testing with MEM-288 in advanced cancers in the current year.
Memgen's COVID-19 vaccine, MemVax, is an adjuvant designed to be used in combination with other COVID-19 vaccines to generate a strong, durable immune response. MemVax is a highly specific immune stimulant that can work with COVID-19 antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax in collaboration with other companies developing complementary COVID-19 vaccines.
https://www.prnewswire.com/news-releases/memgen-announces-research-to-be-presented-at-2020-american-association-of-cancer-research-aacr-meeting-301068860.html